Jack A Roth MD Translational Research
Bench to Bedside Cancer Research
Ismail M. Meraz, Mourad Majidi, Bingliang Fang, Feng Meng, Lihui Gao, RuPing Shao, Renduo Song, Feng Li, Min Jin Ha, Qi Wang, Jing Wang, Elizabeth Shpall, Sung Yun Jung, Franziska Haderk, Philippe Gui, Jonathan Wesley Riess, Victor Olivas, Trever G . Bivona, Jack A. Roth
https://www.biorxiv.org/content/10.1101/2021.12.10.472153v2
The development of acquired drug resistance remains a significant problem. This obstacle to long-term patient survival highlights the need to identify acquired resistance mechanisms. When treated with a tyrosine kinase inhibitor like osimertinib, not all patients respond initially and responses, when they occur, are variable, typically incomplete, and temporary due to acquired drug resistance. PDK1 was found to be a central upstream regulator of two critical drug resistance pathways: PI3K/AKT/mTOR and YAP. PDK1 and its downstream effectors can be targeted with existing drugs in future clinical trials to overcome osimertinib acquired resistance.
Jack A Roth MD Translational Research